Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells


News provided by

I Peace, Inc.; KOSÉ Corporation; Reju, Inc.

Jul 09, 2024, 11:00 ET

Share this article

Share toX

Share this article

Share toX

Demonstration testing of "my own" beauty products

PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku, Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters: Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Minato-ku, Tokyo; CEO: Yurie Kamiya) have agreed to enter a strategic partnership to develop and provide personalized beauty products*1 containing iPSF (iPS cell extract), a unique ingredient derived from each customers' own iPS cells*2. The personalized beauty products will not only contain iPSF but will be formulated in the optimal dosage form and texture to suit each customer's preferences and sensibilities. This innovative approach ensures that customers can enjoy the beauty products meticulously tailored to their needs and desires. Before the end of 2024, the partnership plans to commence demonstration testing of the technical and business aspects of these beauty products, collaborating with medical institutions in Japan.

Continue Reading

*1 Personalized beauty products resulting from this project will be provided through medical institutions under medical supervision, rather than being provided as cosmetics as defined by the Japanese Pharmaceuticals and Medical Devices Act.

*2 iPS cells are a type of stem cell that can proliferate almost indefinitely and differentiate into any type of cell in the various tissues and organs, making them promising for regenerative medicine applications.

Background to the strategic partnership

KOSÉ, a leading company in the business of beauty in Japan as a provider of cosmetics and other products, has joined forces with I Peace, a biotech company working in the field of iPS cell technology, and Reju, a supplier of iPSF. This strategic partnership is driven by a shared commitment to delivering personalized beauty solutions that are tailored to the unique individuality of each customer in a society that respects diversity.

With a focus on the 3G principals of Global, Gender, and Generation, KOSÉ is working on a mission to deliver the value of beauty to as many people as possible by targeting new customer segments, beyond adult women. KOSÉ is committed to providing a wide range of cosmetic products tailored to meet the unique needs of diverse customers including different functions and usability, by leveraging its extensive expertise and strength in cosmetics development and brand creation. To further expand its value propositions beyond the realm of beauty, KOSÉ has been exploring the technical and business aspects in the areas of health and cure, elevating its value propositions to holistic well-being concept.

I Peace, on the other hand, is engaged in a number of businesses including the supply of clinical-grade iPS cells to pharmaceutical companies and cell and gene therapy developers worldwide. Additionally, I Peace offers iPS cell banking services for individuals, enabling them to store their own iPS cells for personalized disease treatment in the future and other applications. Through the groundbreaking technologies, I Peace has significantly reduced the cost of manufacturing iPS cells, paving the way for a future where individuals will be able to make use of their own iPS cells.

With a separate technical partnership with I Peace, Reju is aiming to apply cutting-edge iPS cell component extraction and refining technologies to the areas of beauty and health. Reju is researching and verifying the potential contributions of iPSF, a unique iPS cell extract produced through these advanced technologies, to cell rejuvenation and longevity. The unique iPSF components are expected to have wide-ranging applications across various beauty and healthcare areas.

Recognizing the potential of delivering truly personalized beauty solutions tailored to each customer by combining their expertise in beauty and iPS cell technology, these three companies have come together to form this new strategic partnership.

Outline of the initiative

This initiative aims to provide customers with a wide range of beauty products uniquely tailored to each individual. The process begins with the iPS cells generation from somatic cells which are collected from the customer's own blood. In the process, the extracts of their own iPS cells are taken and stored so the customers can enjoy beauty products containing extracts of their own iPS cells. Because iPS cells are rejuvenated in the cell generation process, customers can benefit from the cellular activity levels similar to their younger selves. Moreover, the use of iPSF derived from the customers' own cells ensures high biocompatibility, minimizing the risk of adverse reactions. In this initiative, I Peace will generate, culture, and manage iPS cells from an individual's somatic cells using its extensive experience in operating personal iPS cell banking services employing its latest biotechnology and stringent safety protocols to ensure the highest quality. Utilizing its technical partnership with I Peace, Reju will manufacture and supply iPSF for the beauty products.

The beauty products offered through this initiative will be tailored to customers' preferences not only in components but also in a dosage form. For example, the personalized beauty products will be available in various forms like gels for those who prefer a fresh feeling, or creams for those concerned about dryness. This versatility ensures each customer's unique desires for usability, feel, and the added value are met, in alignment with the sensibilities they may have. KOSÉ, having developed many different cosmetics in pursuit of ever-better usability, will be in charge of providing the personalized beauty products to customers' satisfaction.

This initiative will appoint Japanese medical institutions who will take care of collecting somatic cells from customers, preparing iPSF-based formulations, and other relevant work, with the aim to commence demonstrating testing before the end of 2024.

Roles of each party

KOSÉ:                 Manufacture and sale of preparations personalized to individual preferences
I Peace:              Generation, cultivation, and management of customers' own iPS cells
Reju:                   Supply of iPSF (iPS cell extract)

Overview of each party

KOSÉ Corporation

Representative:  Kazutoshi Kobayashi, President & CEO
Headquarters:    3-6-2 Nihonbashi, Chuo-ku, Tokyo 103-8251, Japan
Founded in:        1946
Business:            Manufacture and sale of cosmetics
Website:             https://corp.kose.co.jp/en/

I Peace, Inc.

Representative: Koji Tanabe, Founder & CEO
Headquarters:   809 San Antonio Rd., Palo Alto, CA 94303, USA
Founded in:       2015
Business:          Operation of the Personal iPS Cell Banking service, and contract manufacture and sale of clinical- and research-use iPS cells for companies
Website:            https://ipeace.com/en/

Reju, Inc.

Representative: Yurie Kamiya, CEO
Headquarters:   6-15-1 Roppongi , Minato-ku, Tokyo 106-0032, Japan
Founded in:      2022
Business:          Supply of beauty and health products and services using iPSF (iPS cell extract)
URL                  https://rejuinc.com/

Reference: iPS cell research conducted by KOSÉ

As part of its rejuvenation research, KOSÉ has been analyzing and evaluating dermal fibroblasts collected from a single donor from the ages of 36 to 67, as well as iPS cells generated from these cells, to study skin aging. KOSÉ has reported that initialization of differentiated cells into undifferentiated iPS cells restores the length of telomeres (the terminal portion of chromosomes that shortens with each cell division) in all aged cells. In another approach, KOSÉ has succeeded in inducing dermal fibroblasts to differentiate into new dermal fibroblasts via iPS cells, and has ascertained that the quality of mitochondria was restored in dermal fibroblasts induced from these iPS cells when compared with the original cells.

Reference: About I Peace

I Peace was founded in 2015 by Dr. Koji Tanabe, a graduate of Professor Shinya Yamanaka's laboratory at Kyoto University and the second author of the landmark paper on the world's first human iPS cell line. Dr. Tanabe has been involved in iPS cell research since it's early days. By manufacturing and selling cells for clinical and research use, I Peace aims to quickly bring a variety of useful iPS cell technologies to the world. Recognizing the unique advantage of iPS cells—being able to generate them from anyone and use them for personalized treatment—I Peace launched the Personal iPS Cell Banking service with the commitment to making it possible for individuals to obtain and use their own cells for personalized disease treatment. The I Peace cell manufacturing facility has been licensed by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to manufacture specified processed cells and is also registered with the FDA in the United States. I Peace supplies clinical-grade iPS cells to pharmaceutical companies and cell therapy development companies worldwide.

Reference: About Reju

Focusing on the rejuvenating effect of iPS cells, Reju entered a technical partnership with I Peace and conducted research and development with the aim of applying iPS cell technology to rejuvenation, both inside and out, to improve the quality of life in an era of 100-year life spans. Through extensive research and development efforts, Reju has developed iPSF (iPS cell extract), innovative product that encapsulates the rejuvenation properties of iPS cells. Reju values science and evidence-based approach to make a contribution to the next-generation of personal beauty and healthcare, going beyond existing products and services in anti-aging industry.

SOURCE I Peace, Inc.; KOSÉ Corporation; Reju, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.